OtherPancreatic cancer

The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026

J Hematol Oncol · 2026Not reported in the abstract

Pillozzi S, Giommoni E, Petroni G, Rossini D, Lavacchi D, Brugia M, et al. J Hematol Oncol. 2026. 19:53

Study type: Other
Study name: RASolute-302
Design: Scientific correspondence reviewing the phase 3 RASolute-302 trial and data presented at ASCO 2026; not the primary trial report
Sample size: Not reported in the abstract
Source: J Hematol Oncol · 2026

In plain words

For years, metastatic pancreatic cancer has had limited treatment options after the first treatment stops working. According to this article, a new drug called daraxonrasib, which targets the RAS family of genes, has raised the median survival in second-line treatment from 6.6 to 13.2 months. Other targeted drugs for specific KRAS mutations are also being studied. Be sure to talk to your treating doctor about whether these treatments are right for you.

Key results

13.2 vs 6.6 months

Median overall survival (daraxonrasib vs chemotherapy, second line)

Median overall survival nearly doubled

Nearly doubled compared with chemotherapy

Progression-free survival

Exact figure not given in the abstract

Dose and schedule cards

Daraxonrasib (RASolute 302)

Metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or patients unfit for multiagent therapy (FDA label); ESMO: RAS G12 mutation and ECOG 0–1Cycle length: ContinuousOn the page “Pancreatic cancer” · Metastatic disease: first-line, maintenance and later lines

Metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or patients unfit for multiagent therapy (FDA label); ESMO: RAS G12 mutation and ECOG 0–1

Drug	Dose	Route	Schedule
Daraxonrasib	300 mg once daily	Oral	Continuous

Cycle length: Continuous
Duration: Until disease progression or unacceptable toxicity

Dose from the FDA label; evidence: RASolute 302.

Skin toxicity prevention from the start of treatment: a topical corticosteroid and a moisturizing cream on the face and chest, limiting sun exposure and using sunscreen with SPF 30 or higher, and considering prophylactic oral doxycycline or minocycline. Dose reduction to 200 mg, then to 150 mg; discontinue if 150 mg is not tolerated; grade 3 rash, stomatitis or diarrhoea → withhold until grade ≤1, then resume at a lower dose.

On the page “Pancreatic cancer” · Metastatic disease: first-line, maintenance and later lines

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Treatment arms and regimens

1Daraxonrasib (RMC-6236)

First-in-class pan-RAS (ON) inhibitor, in second-line treatment of mPDAC. Dose details in the full text of the paper.

2Chemotherapy (comparator group)

Standard second-line chemotherapy. The exact regimen and dose details are in the full text of the paper.

Source of the regimen details: Abstract of the paper; dose not stated in the abstract, and dose details should be checked in the full text of the original RASolute-302 trial paper

Doses are given for the information of specialists, as in this study’s protocol, and are not a prescription. Every drug must be prescribed by the treating physician for the individual patient.

Study population

Patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving second-line treatment (based on the abstract's description of the RASolute-302 trial). Detailed eligibility criteria are not given in the abstract.

Endpoints

The abstract compares median overall survival (OS) and progression-free survival (PFS). Primary and secondary endpoints are not formally defined in the abstract.

Safety and side effects

Safety data (grade 3 or higher adverse events) are not reported in the abstract. The abstract only notes that allele-specific strategies are designed to optimise target engagement and safety.

Clinical significance and place in guidelines

According to the authors, by nearly doubling median overall survival compared with chemotherapy in second-line mPDAC, daraxonrasib has established a new standard of care. Allele-specific strategies (G12D and G12C) and combinations are still under investigation, and the authors see liquid biopsy-guided optimisation of drug sequencing or combination as the way forward. The status of drug approvals and formal guideline recommendations should be checked separately, as the abstract does not address them.

Limitations

This text is a scientific correspondence and not the primary trial report. The abstract does not give the sample size, hazard ratio, confidence interval, P value, exact progression-free survival or safety data. Data on allele-specific strategies come from conference presentations, and the original sources should be consulted for a precise judgement. Several authors declared conflicts of interest with pharmaceutical companies.

Original article (DOI)PubMed

This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.